Azabicyclic compounds for the treatment of disease

Abstract

The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.

1 . A method for treating a disease or condition in a mammal in need thereof, wherein the mammal would receive symptomatic relief from the administration of an α7 nicotinic acetylcholine receptor agonist comprising administering to the mammal a therapeutically effective amount of a compound according to Formula I:  
       
         
           
           
               
               
           
         
       
       wherein Azabicyclo is  
       
         
           
           
               
               
           
         
         R 1  is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;  
         R 2  is H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;  
         k is 1 or 2, provided that when k is 2, each R 2  is other than H;  
         R 3  is H, lower alkyl, lower substituted alkyl, or lower halogenated alkyl;  
         W 1  is O, S, or N(R 15 );  
         W 5  and W 6  are independently H or a bond to the carbonyl of Formula I, provided that only one of W 5  and W 6  is said bond and the other is H;  
         Each R 4  is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocylcoalkyl, phenyl, substituted phenyl, —OR 10 , —SR 10 , —SOR 10 , —SO 2 R 10 , —NR 10 C(O)R 5 , —NR 10 C(O)R 6 , —NR 10 C(O)R 8 , —N(R 10 ) 2 , —NO 2 , —C(O)R 10 , —CN, —C(O) 2 R 10 , —C(O)NHR 10 , —SCN, —S(O)NHR 10 , —S(O) 2 NHR 10 , —NR 10 S(O) 2 R 10 , R 5 , or R 6 , provided that when R 4  is —SO 1-2 R 10  or —CO 12 R 10  and R 10  is heterocycle, halogenated heterocycle or heterocycle substituted with 1 substitutent selected from R 13 , a carbon in the heterocycle is bonded to the carbon or sulfur;  
         m is 1 or 2, provided that when m is 2 each R 4  is other than H;  
         R 5  is a 5-membered heteroaromatic mono-cyclic moiety containing within the ring 1-3 heteroatoms independently selected from the group consisting of —O—, ═N—, —N(R 16 )—, and —S—, and having 0-1 substituent selected from R 1 , and further having 0-3 substituents independently selected from F, Cl, Br, or I,  
         or R 5  is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each A is independently CR 14  or N, provided that only up to one A is N, E 1  and E 2  are independently selected from CR 14 , O, S, or NR 16 , and G is CR 14 , provided that R 14  or R 16  can be a bond when — forms a double bond and further provided that only one R 14  or R 16  can be a bond for bonding R 5  to a moiety to which it is attached;  
         R 6  is a 6-membered heteroaromatic mono-cyclic moiety containing within the ring 1-3 heteroatoms selected from ═N— and having 0-1 substituent selected from R 9  and 0-3 substituent(s) independently selected from F, Cl, Br, or I,  
         or R 6  is a 10-membered heteroaromatic bi-cyclic moiety containing within one or both rings 1-3 heteroatoms selected from ═N—, each 10-membered fused-ring moiety having 0-1 substituent selected from R 9 , and 0-3 substituent(s) independently selected from F, Cl, Br, or I;  
         R 7  is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and R 9 :  
         Each R 8  is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 9 ;  
         R 9  is alkyl, substituted alkyl, halogenated alky, —OR 11 , —CN, —NO 2 , —NR 10 R 10 ;  
         Each R 10  is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R 13 , cycloalkyl substituted with I substituent selected from R 13 , heterocycloalkyl substituted with 1 substituent selected from R 13 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;  
         Each R 11  is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;  
         R 12  is —OR 11 , —SR 11 , alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —N(R 11 ) 2 , R 11 , —NO 2 , —CN(R 11 ) 2 , —CN, —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , or —NR 11 S(O) 2 R 11 ;  
         R 13  is —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —SOR 11 , —SO 2 R 11 , —C(O)NR 11 R 11 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , or —NO 2 ;  
         Each R 14  is independently bond, H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —NO 2 , —C(O)N(R 11 ) 2 , —CN, —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , F, Cl, Br, I, or a bond, provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —NO 2 , —C(O)N(R 11 ) 2 , —CN, —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , or —NR 11 S(O) 2 R 11 , and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;  
         R 15  is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;  
         Each R 16  is independently bond, H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;  
         Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;  
         Substituted phenyl is a phenyl either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R 12  and 0-3 substituents independently selected from F, Cl, Br, or I;  
         Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R 12  and 0-3 substituents independently selected from F, Cl, Br, or I, where the substitution can be independently on either only one ring or both rings of said naphthalene moiety;  
         Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms;  
         Lower alkyl is both straight- and branched-chain moieties having from 1-4 carbon atoms;  
         Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;  
         Lower halogenated alkyl is an alkyl moiety having from 1-4 carbon atoms and having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;  
         Substituted alkyl is an alkyl moiety from 1-6 carbon atoms and having 0-3 substituents independently selected from R 5 , R 6 , F, Cl, Br, or I and further having 1 substituent selected from —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —CN, —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, or phenyl having 1 substituent selected from R 9  and further having 0-3 substituents independently selected from F, Cl, Br, or I:  
         Lower substituted alkyl is lower alkyl having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from —OR 10 , —SR 10 , —NR 10 ) 2 , —C(O)R 10 , —C(O)N(R 10)   2 , —CN, —NR 10 C(OR 10 , —S(O) 2 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, R 5 , or R 6 ,  
         wherein each R 10  is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl.  
         wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl and up to one other substituent independently selected from —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —C(O)N(R 11 ) 2 , —CN, —CF, NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11  or —NO 2 ,  
         and wherein each R 11  is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl:  
         Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond:  
         Lower alkenyl is straight- and branched-chain moieties having from 2-4 carbon atoms and having at least one carbon-carbon double bond:  
         Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n−1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety:  
         Lower halogenated alkenyl is an unsaturated alkenyl moiety having from 2-4 carbon atoms and having 1 to (2n−1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety:  
         Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R 5 , R 6 , —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , —CN, phenyl, or phenyl having 1 substituent selected from R 9 , and further having 0-3 substituents independently selected from F, Cl, Br, or I:  
         Lower substituted alkenyl is lower alkenyl having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from R 5 , R 6 , —CN, —OR 10 , —SR 10 , —N(R 10 ), —C(O)R 10 , —C(O)N(R 10 ) 2 , —NR 10 C(O)R 10 , —S(O) 2 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, R 5 , or R 6 ,  
         wherein each R 10  is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl.  
         wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl and up to one other substituent independently selected from —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —C(O)N(R 11 ) 2 , —CN, —CF 3 , —NR 11 OR 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , or —NO 2 ,  
         and wherein each R 11  is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl:  
         Alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond:  
         Lower alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond:  
         Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n−3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety:  
         Lower halogenated alkynyl is an unsaturated alkynyl moiety having from 3-4 carbon atoms and having 1 to (2n−3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety:  
         Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R 5 , R 6 , —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , —CN, phenyl, or phenyl having 1 substituent selected from R 9 , and further having 0-3 substituents independently selected from F, Cl, Br, or I:  
         Lower substituted alkynyl is lower alkynyl having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R 5 , R 6 , —OR 10 , —SR 10 , —N(R 10 ) 2 , —C(O)R 10 , —C(O)N(R 10 ) 2 , —CN, —NR 10 C(O)R 10 , —S(O) 2 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, R 5 , or R 6 ,  
         wherein each R 10  is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl,  
         wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl and up to one other substituent independently selected from —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —C(O)N(R 11 ) 2 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , or —NO 2 ,  
         and wherein each R 11  is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl;  
         Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms;  
         Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from F, or Cl;  
         Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —CN, —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, or phenyl having 1 substituent selected from R 9 , and further having 0-3 substituents independently selected from F, Cl, Br, or I;  
         Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 7 )—, or —O—;  
         Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 7 )—, or —O—, and having 1-4 substituents independently selected from F, or Cl;  
         Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 7 )—, or —O— and having 0-3 substituents independently selected from —F, or —Cl, and further having 1 substituent selected from R 5 , R 6 , —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —CN, —NR 10 C(O)R 10 , —NO 2 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having 1 substituent selected from R 9  and further having 0-3 substituents independently selected from F, Cl, Br, or I;  
         Lactam heterocycloalkyl is a cyclic moiety having from 4-7 atoms with one atom being only nitrogen with the bond to the lactam heterocycloalkyl thru said atom being only nitrogen and having a ═O on a carbon adjacent to said nitrogen, and having up to 1 additional ring atom being oxygen sulfur, or nitrogen and further having 0-2 substituents selected from F, Cl, Br, I, or R 1  where valency allows;  
         or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, and pure enantiomer thereof.  
       
     
     
         2 . The method of  claim 1 , wherein m is 1.  
     
     
         3 . (Cancel)  
     
     
         4 . (Cancel)  
     
     
         5 . The method of  claim 2 , wherein R 2  is H, or methyl.  
     
     
         6 . The method of  claim 5 , wherein W is 5-benzofuranyl, 6-benzofuranyl, 5-benzothienyl, or 6-benzothienyl, any of which is optionally substituted with lower alkyl, lower halogenated alkyl, lower alkynyl, halogen, cyano, aminocarbonyl, formyl, or acetyl.  
     
     
         7 . The method of  claim 6 , wherein Azabicyclo is II.  
     
     
         8 . The method of  claim 7 , wherein the compound is 
 N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-methyl-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-methyl-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-cyano-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-cyano-1-benzofuran-5-carboxamide;    N-6-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-2,6-dicarboxamide;    N-5-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-2,5-dicarboxamide;    2-acetyl-N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-6-carboxamide;    2-acetyl-N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-formyl-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-2-formyl-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methyl-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-methyl-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-isopropyl-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-chloro-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-chloro-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromo-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-bromo-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-ethynyl-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-prop-1-ynyl-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-cyano-1-benzofuran-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-3-cyano-1-benzofuran-5-carboxamide;    N-6-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-3,6-dicarboxamide;    N-5-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzofuran-3,5-dicarboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1-benzothiophene-5-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1H-indole-6-carboxamide;    N-[(exo-4S)-1-azabicyclo[2.2.1]hept-3-yl]-1H-indole-5-carboxamide; or a    pharmaceutically acceptable salt thereof.    
     
     
         9 . The method of  claim 6 , wherein Azabicyclo is III and k is 1.  
     
     
         10 . The method of  claim 9 , wherein the compound is 
 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-cyano-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)]-2-cyano-1-benzofuran-5-carboxamide;    N-6-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-2,6-dicarboxamide;    N-5-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-2,5-dicarboxamide;    2-acetyl-N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-6-carboxamide;    2-acetyl-N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-formyl-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-2-formyl-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-isopropyl-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-chloro-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-chloro-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-bromo-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethynyl-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-cyano-1-benzofuran-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;    N-6-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-3,6-dicarboxamide;    N-5-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzofuran-3,5-dicarboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzothiophene-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1-benzothiophene-5-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1H-indole-6-carboxamide;    N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]-1H-indole-5-carboxamide; or a    pharmaceutically acceptable salt thereof.    
     
     
         11 . The method of  claim 6 , wherein Azabicyclo is IV and k is 1.  
     
     
         12 . The method of  claim 11 , wherein the compound is 
 N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-2-methyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-2-methyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-2-cyano-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-2-cyano-1-benzofuran-5-carboxamide;    N-6-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzofuran-2,6-dicarboxamide;    N-5-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzofuran-2,5-dicarboxamide;    2-acetyl-N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzofuran-6-carboxamide;    2-acetyl-N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-2-formyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-2-formyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-methyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-methyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-isopropyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-chloro-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-chloro-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-bromo-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-bromo-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-ethynyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-prop-1-ynyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-cyano-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-3-cyano-1-benzofuran-5-carboxamide;    N-6-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzofuran-3,6-dicarboxamide;    N-5-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzofuran-3,5-dicarboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzothiophene-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1-benzothiophene-5-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1H-indole-6-carboxamide;    N-[(3R)-1-azabicyclo[3.2.2]non-3-yl]-1H-indole-5-carboxamide; or a pharmaceutically    acceptable salt thereof.    
     
     
         13 . The method of  claim 6 , wherein Azabicyclo is V or VI and R 3  is H.  
     
     
         14 . The method of  claim 13 , wherein the compound is 
 N-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-2-methyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-2-methyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-2-cyano-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-2-cyano-1-benzofuran-5-carboxamide;    N-6-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzofuran-2,6-dicarboxamide;    N-5-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzofuran-2,5-dicarboxamide;    2-acetyl-N-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzofuran-6-carboxamide;    2-acetyl-N-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-2-formyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-2-formyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-methyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-methyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-isopropyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-isopropyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-chloro-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-chloro-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-bromo-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-bromo-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-ethynyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-ethynyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-prop-1-ynyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-prop-1-ynyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-cyano-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-3-cyano-1-benzofuran-5-carboxamide;    N-6-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzofuran-3,6-dicarboxamide;    N-5-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzofuran-3,5-dicarboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzothiophene-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-5-yl)-1-benzothiophene-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-2-methyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-2-methyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-2-cyano-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-2-cyano-1-benzofuran-5-carboxamide;    N-6-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzofuran-2,6-dicarboxamide;    N-5-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzofuran-2,5-dicarboxamide;    2-acetyl-N-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzofuran-6-carboxamide;    2-acetyl-N-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-2-formyl- I -benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-2-formyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-methyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-methyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-isopropyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-isopropyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-chloro-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-chloro-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-bromo-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-bromo-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-ethynyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-ethynyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-prop-1-ynyl-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-prop-1-ynyl-1-benzofuran-5-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-cyano-1-benzofuran-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-3-cyano-1-benzofuran-5-carboxamide;    N-6-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzofuran-3,6-dicarboxamide;    N-5-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzofuran-3,5-dicarboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzothiophene-6-carboxamide;    N-(2-azabicyclo[2.2.1]hept-6-yl)-1-benzothiophene-5-carboxamide; or pharmaceutically acceptable salt thereof.    
     
     
         15 - 22 . (Delete)  
     
     
         23 . A method for treating a disease or condition in a mammal in need thereof, wherein the mammal would receive symptomatic relief from the administration of an α7 nicotinic acetylcholine receptor agonist comprising administering to the mammal a therapeutically effective amount of a compound according to Formula I:  
       
         
           
           
               
               
           
         
       
       wherein Azabicyclo is  
       
         
           
           
               
               
           
         
         R 1  is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;  
         R 2  is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;  
         W 1  is O, S, or N(R 15 );  
         W 5  and W 6  are independently H or a bond to the carbonyl of Formula I, provided that only one of W 5  and W 6  is said bond and the other is H;  
         Each R4 is independently H, F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocylcoalkyl, phenyl, substituted phenyl, —OR 10 , —SR 10 , —SOR 10 , —SO 2 R 10 , —NR 10 C(O)R 5 , —NR 10 C(O)R 6 , —NR 10 C(O)R 8 , —N(R 10 ) 2 , —NO 2 , —C(O)R 10 , —CN, —C(O) 2 R 10 , —C(O)NHR 10 , —SCN, —S(O)NHR 10 , —S(O) 2 NHR 10 , —NR 10 S(O) 2 R 10 , R 5 , or R 6 , provided that when R4 is —SO 1-2 R 10  or —CO 1-2 R 10  and R 10  is heterocycle, halogenated heterocycle or heterocycle substituted with 1 substitutent selected from R 13 , a carbon in the heterocycle is bonded to the carbon or sulfur;  
         m is 1 or 2, provided that when m is 2 each R 4  is other than H;  
         R 5  is a 5-membered heteroaromatic mono-cyclic moiety containing within the ring 1-3 heteroatoms independently selected from the group consisting of —O—, ═N—, —N(R 16 )—, and —S—, and having 0-1 substituent selected from R 9 , and further having 0-3 substituents independently selected from F, Cl, Br, or I,  
         or R 5  is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula  
         
           
             
             
                 
                 
             
           
         
         wherein each A is independently CR 14  or N, provided that only up to one A is N, E 1  and E 2  are independently selected from CR 14 , O, S, or NR 16 , and G is CR 14 , provided that R 14  or R 16  can be a bond when — forms a double bond and further provided that only one R 14  or R 16  can be a bond for bonding R 5  to a moiety to which it is attached;  
         R 6  is a 6-membered heteroaromatic mono-cyclic moiety containing within the ring 1-3 heteroatoms selected from ═N— and having 0-1 substituent selected from R 9  and 0-3 substituent(s) independently selected from F, Cl, Br, or I,  
         or R 6  is a 10-membered heteroaromatic bi-cyclic moiety containing within one or both rings 1-3 heteroatoms selected from ═N—, each 10-membered fused-ring moiety having 0-1 substituent selected from R 9 , and 0-3 substituent(s) independently selected from F, Cl, Br, or I;  
         R 7  is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and R 9 ;  
         Each R 8  is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 9 ;  
         R 9  is alkyl, substituted alkyl, halogenated alky, —OR 11 , —CN, -NO 2 , —NR 10 R 10 ;  
         Each R 10  is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R 13 , cycloalkyl substituted with 1 substituent selected from R 13 , heterocycloalkyl substituted with I substituent selected from R 13 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;  
         Each R 11  is independently H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;  
         R 12 , —OR 11 , —SR 11 , alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —N(R 11 ) 2 , —C(O)R 11 , —NO 2 , —C(O)N(R 11 ) 2 , —CN, —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , or —NR 11 S(O) 2 R 11 ,  
         R 13  is —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —SOR 11 , —SO 2 R 11 , —C(O)NR 11 R 11 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , or —NO 2 ;  
         Each R 14  is independently bond, H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —NO 2 , —C(O)N(R 11 ) 2 , —CN, —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 F, Cl, Br, I, or a bond, provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —NO 2 , —C(O)N(R 11 ) 2 , —CN, —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , or —NR 11 S(O) 2 R 11 , and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;  
         R 15  is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;  
         Each R 16  is independently bond, H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;  
         Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;  
         Substituted phenyl is a phenyl either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R 12  and 0-3 substituents independently selected from F, Cl, Br, or I;  
         Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R 12  and 0-3 substituents independently selected from F, Cl, Br, or I, where the substitution can be independently on either only one ring or both rings of said naphthalene moiety;  
         Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms;  
         Lower alkyl is both straight- and branched-chain moieties having from 1-4 carbon atoms;  
         Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;  
         Lower halogenated alkyl is an alkyl moiety having from 1-4 carbon atoms and having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;  
         Substituted alkyl is an alkyl moiety from 1-6 carbon atoms and having 0-3 substituents independently selected from R 5 , R 6 , F, Cl, Br, or I and further having 1 substituent selected from —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —CN, —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, or phenyl having 1 substituent selected from R 9  and further having 0-3 substituents independently selected from F, Cl, Br, or I;  
         Lower substituted alkyl is lower alkyl having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from —OR 10 , —SR 10 , —N(R 10 ) 2 , —C(O)R 10 , —C(O)N(R 10 ) 2 , —CN, —NR 10 C(O)R 10 , —S(O) 2 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, R 5 , or R 6 ,  
         wherein each R 10  is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl,  
         wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl and up to one other substituent independently selected from —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —C(O)N(R 11 ) 2 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , or —NO 2 ,  
         and wherein each R 11  is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl;  
         Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;  
         Lower alkenyl is straight- and branched-chain moieties having from 2-4 carbon atoms and having at least one carbon-carbon double bond;  
         Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n−1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;  
         Lower halogenated alkenyl is an unsaturated alkenyl moiety having from 2-4 carbon atoms and having 1 to (2n−1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;  
         Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R 5 , R 6 , —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , —CN, phenyl, or phenyl having 1 substituent selected from R 9 , and further having 0-3 substituents independently selected from F, Cl, Br, or I;  
         Lower substituted alkenyl is lower alkenyl having 0-3 substituents independently selected from F, Cl, Br, or I, and further having 1 substituent selected from R 5 , R 6 , —CN, —OR 10 , —SR 10 , —N(R 10 ) 2 , —C(O)R 10 , —C(O)N(R 10 ) 2 , —NR 10 C(O)R 10 , —S(O) 2 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, R 5 , or R 6 ,  
         wherein each R 10  is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl,  
         wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl and up to one other substituent independently selected from —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —C(O)N(R 11 ) 2 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 or —NO 2 ,  
         and wherein each R 11  is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl;  
         Alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;  
         Lower alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;  
         Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n−3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;  
         Lower halogenated alkynyl is an unsaturated alkynyl moiety having from 3-4 carbon atoms and having 1 to (2n−3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;  
         Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R 5 , R 6 , —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , —CN, phenyl, or phenyl having 1 substituent selected from R 9 , and further having 0-3 substituents independently selected from F, Cl, Br, or I;  
         Lower substituted alkynyl is lower alkynyl having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from R 5 , R 6 , —OR 10 , —SR 10 , —N(R 10 ) 2 , —C(O)R 10 , —C(O)N(R 10 ) 2 , —CN, —NR 10 C(O)R 10 , —S(O) 2 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, R 5 , or R 6 ,  
         wherein each R 10  is independently H, lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl,  
         wherein any lower alkyl, cycloalkyl, heterocycloalkyl, or phenyl is optionally substituted with up to two halogens independently selected from F or Cl and up to one other substituent independently selected from —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —C(O)N(R 11 ) 2 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , or —NO 2 ,  
         and wherein each R 11  is independently H, lower alkyl, lower cycloalkyl, heterocycloalkyl, lower halogenated alkyl, lower halogenated cycloalkyl, or halogenated heterocycloalkyl;  
         Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms:  
         Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from F, or Cl;  
         Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, or Cl, and further having 1 substituent selected from —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —CN, —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , —NO 2 , phenyl, or phenyl having 1 substituent selected from R 9 , and further having 0-3 substituents independently selected from F, Cl, Br, or I;  
         Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 7 )—, or —O—;  
         Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 7 )—, or —O—, and having 1-4 substituents independently selected from F, or Cl;  
         Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 7 )—, or —O— and having 0-3 substituents independently selected from —F, or —Cl, and further having 1 substituent selected from R 5 , R 6 , —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —CN, —NR 10 C(O)R 10 , —NO 2 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having 1 substituent selected from R 9  and further having 0-3 substituents independently selected from F, Cl, Br, or I;  
         Lactam heterocycloalkyl is a cyclic moiety having from 4-7 atoms with one atom being only nitrogen with the bond to the lactam heterocycloalkyl thru said atom being only nitrogen and having a ═O on a carbon adjacent to said nitrogen, and having up to 1 additional ring atom being oxygen, sulfur, or nitrogen and further having 0-2 substituents selected from F, Cl, Br, I, or R 9  where valency allows:  
         or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.  
       
     
     
         24 . The method of  claim 23 , wherein R 1  is H, lower alkyl, or cycloalkyl.  
     
     
         25 . (Delete)  
     
     
         26 . The method of  claim 24 , wherein R 2  is H, or methyl.  
     
     
         27 . The method of  claim 26 , wherein m is 1 and W is 5-benzofuranyl, 6-benzofuranyl, 5-benzothienyl, or 6-benzothienyl, any of which is optionally substituted with lower alkyl, lower halogenated alkyl, lower alkynyl, halogen, cyano, aminocarbonyl, formyl, or acetyl.  
     
     
         28 . (Delete)  
     
     
         29 . The method of  claim 27 , wherein the compound is 
 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-cyano-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-cyano-1-benzofuran-5-carboxamide;    N-6-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2,6-dicarboxamide;    N-5-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2,5-dicarboxamide;    2-acetyl-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;    2-acetyl-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-formyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-formyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chloro-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chloro-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;    N-6-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-3,6-dicarboxamide;    N-5-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-3,5-dicarboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide;    N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide; or a    pharmaceutically acceptable salt thereof.    
     
     
         30 . The method of  claim 27 , wherein the compound is 
 N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-methyl-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-cyano-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-(1-azabicyclo[2.2.2]oct-3-yl)]-2-cyano-1-benzofuran-5-carboxamide;    N-6-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2,6-dicarboxamide;    N-5-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2,5-dicarboxamide;    2-acetyl-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-6-carboxamide;    2-acetyl-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-formyl-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-formyl-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-chloro-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-chloro-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-ethynyl-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-prop-1-ynyl-1-benzofuran-5-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1-benzofuran-5-carboxamide;    N-6-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-3,6-dicarboxamide;    N-5-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-3,5-dicarboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-6-carboxamide;    N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-5-carboxamide; or    pharmaceutically acceptable salt thereof.    
     
     
         31 - 44 . (Delete)  
     
     
         45 . The method of  claim 1 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.  
     
     
         46 . The method of  claim 1 , wherein the disease or condition is attention deficit disorder, or attention deficit hyperactivity disorder.  
     
     
         47 . The method of  claim 1 , wherein the disease or condition is depression, general anxiety disorder, or post traumatic stress disorder.  
     
     
         48 . The method of  claim 1 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia, or senile dementia.  
     
     
         49 . The method of  claim 1 , wherein the disease or condition is schizophrenia or psychosis.  
     
     
         50 . The method of  claim 8 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, or symptoms associated with pain.  
     
     
         51 . The method of  claim 10 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, or symptoms associated with pain.  
     
     
         52 . The method of  claim 12 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, or symptoms associated with pain.  
     
     
         53 . The method of  claim 23 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.  
     
     
         54 . The method of  claim 23 , wherein the disease or condition is attention deficit disorder, attention deficit hyperactivity disorder, depression, general anxiety disorder, post traumatic stress disorder, cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia, senile dementia, schizophrenia, psychosis, or symptoms associated with pain.  
     
     
         55 . The method of  claim 23 , wherein the disease or condition is attention deficit disorder, or attention deficit hyperactivity disorder.  
     
     
         56 . The method of  claim 23 , wherein the disease or condition is depression, general anxiety disorder, or post traumatic stress disorder.  
     
     
         57 . The method of  claim 23 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia, or senile dementia.  
     
     
         58 . The method of  claim 23 , wherein the disease or condition is schizophrenia or psychosis.  
     
     
         59 . The method of  claim 29 , wherein the disease or condition is cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, or symptoms associated with pain.  
     
     
         60 . The method of  claim 29 , wherein the disease or condition is attention deficit disorder, attention deficit hyperactivity disorder, depression, general anxiety disorder, post traumatic stress disorder, cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia, senile dementia, schizophrenia, psychosis, or symptoms associated with pain.